LARIAM 250 mg, comprimé sécable

USDailyMed:Mefloquine AU:B3 P01BC02(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-only [(R*,S*)-2,8-Bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol 53230-10-7Y 40692 DB00358Y 37171Y TML814419R D04895Y ChEMBL416956N 005218 DTXSID50860636 Interactive image FC(F)(F)c2cccc1c(cc(nc12)C(F)(F)F)[C@H](O)[C@@H]3NCCCC3 InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2/t12-,15+/m1/s1YKey:XEEQGYMUWCZPD‍‍‍‍‍‍​​​‍​​​​​​N-DOMZBBRYSA-NY Mefloquine, sold under the brand nameLariamamong others, is amedicationused to prevent or treatmalaria.When used for prevention it is typically started before potential exposure and continued for several weeks after potential exposure.It can be used to treat mild or moderate malaria but is not recommended for severe malaria.It is takenby mouth. Common side effects include vomiting, diarrhea, headaches, sleep disorders, and a rash.Serious side effects include potentially long-term mental health problems such asdepression,hallucinations, andanxietyand neurological side effects such aspoor balance,seizures, andringing in the ears.It is therefore not recommended in people with a history of mental health problems orepilepsy.It appears to be safe duringpregnancyandbreastfeeding. Mefloquine was developed by the United States Army in the 1970s and came into use in the mid-1980s.It is on theWorld Health Organization's List of Essential Medicines.It is available as ageneric medication.